Psychiatr. praxi. 2025;26(3):184-188 | DOI: 10.36290/psy.2025.030

The impact of opioids and substitution treatment on cognitive functions

Mgr. Aneta Votavová, Mgr. Lenka ©»astná, Ph.D.
Klinika adiktologie, Vąeobecná fakultní nemocnice, 1. lékařská fakulta Univerzity Karlovy, Praha

This theoretical article focuses on the relationship between opiates and cognitive functions, which can lead to significant changes ranging from acute effects to long-term deficits. Published studies indicate impaired cognitive functions, with some difficulties persisting even during abstinence. Prenatal opioid exposure is associated with high risks for child development, underscoring the importance of prevention and support for pregnant users. Although substitution treatment reduces the incidence of relapse, it may continue to negatively affect cognitive status. Contradictory research findings stem from various factors, such as differing methodologies, comorbidities, and socio-economic influences. Nevertheless, a partial restoration of cognitive abilities is seen in some clients following prolonged abstinence or during stabilized substitution therapy. The optimal approach likely involves combining substitution treatment with cognitive rehabilitation and tailoring therapeutic strategies to the individual.

Keywords: opioids, substitution treatment, cognitive functions, executive functions, addictology, cognitive impairment.

Accepted: October 15, 2025; Published: November 6, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Votavová A, ©»astná L. The impact of opioids and substitution treatment on cognitive functions. Psychiatr. praxi. 2025;26(3):184-188. doi: 10.36290/psy.2025.030.
Download citation

References

  1. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2024: Heroin and other opioids - the current situation in Europe [Internet]. Luxembourg: Publications Office of the European Union; 2024 [cited 2025 Apr 19]. Available from: https://www.euda.europa.eu/publications/european-drug-report/2024/heroin-and-other-opioids_en
  2. Chomynová P, Dvořáková Z, Grohmannová K, et al. Zpráva o nelegálních drogách v České republice 2024 [Report on Illicit Drugs in the Czech Republic 2024]. Chomynová P, editor. Praha: Úřad vlády České republiky; 2024.
  3. ©lamberová R. Cognitive functions - Opioid system and gonadal hormones. Psychiatrie. 2005;9:120-4.
  4. Bartoą A. Cognitive functions, activities of daily living and cognitive syndromes. Psychiatr. praxi. 2022;23(2):91-7. doi: 10.36290/psy.2022.021. Go to original source...
  5. Alzu'bi A, Baker WB, Al-Trad B, et al. The impact of chronic fentanyl administration on the cerebral cortex in mice: Molecular and histological effects. Brain Res Bull. 2024;209:110917. doi: 10.1016/j.brainresbull.2024.110917. Go to original source... Go to PubMed...
  6. Sanjari Moghaddam H, Shadloo B, Shahkhah H, et al. Cognitive impairment in opium use disorder. Behav Neurol. 2021;2021:5548623. doi: 10.1155/2021/5548623. Go to original source... Go to PubMed...
  7. Anbalagan S, Falkowitz DM, Mendez MD. Neonatal Abstinence Syndrome. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024.
  8. Stará V, Lesná P, Fencl F, et al. Abstinenční syndrom novorozence a kojence a jeho léčba. Pediatrie pro praxi. 2009;10(6):382-4.
  9. Psederska E, Vassileva J. Neurocognitive impulsivity in opiate users at different lengths of abstinence. Int J Environ Res Public Health. 2023;20(2):1236. doi: 10.3390/ijerph20021236. Go to original source... Go to PubMed...
  10. Ayoobi F, Bidaki R, Shamsizadeh A, et al. Impact of opium dependency on clinical and neuropsychological indices of multiple sclerosis patients. Neurol Sci. 2019;40(12):2501-7. doi: 10.1007/s10072-019-03971-8. Go to original source... Go to PubMed...
  11. Bhatia G, Ganesh R, Kulkarni A. Cognitive impairment in opioid use disorders: Is there a case for use of nootropics? Psychiatry Res. 2023;326:115335. doi: 10.1016/j.psychres.2023.115335. Go to original source... Go to PubMed...
  12. Kozák J, Lejčko J, Fricová J, et al. Opioidy v léčbě chronické nenádorové bolesti: klinický souhrn [Internet]. 3. vyd. Praha: Ústav zdravotnických informací a statistiky ČR; 2020 [cited 2025 Apr 19]. Available from: https://kdp.uzis.cz/res/guideline/18-opioidy-v-lecbe-chronicke-nenadorove-bolesti-final.pdf.
  13. Kroll SL, Nikolic E, Bieri F, et al. Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. Psychopharmacology (Berl). 2018;235(12):3451-64. doi: 10.1007/s00213-018-5060-z. Go to original source... Go to PubMed...
  14. Kamboj SK, Tookman A, Jones L, et al. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain. 2005;117(3):388-95. doi: 10.1016/j.pain.2005. 06. 022. Go to original source...
  15. Rapeli P, Kivisaari R, Autti T, et al. Cognitive function during early abstinence from opioid dependence: A comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry. 2006;6(1):9. doi: 10.1186/1471-244X-6-9. Go to original source... Go to PubMed...
  16. Rass O, Kleykamp BA, Vandrey RG, et al. Cognitive performance in methadone maintenance patients: Effects of time relative to dosing and maintenance dose level. Exp Clin Psychopharmacol. 2014;22(3):248-56. doi: 10.1037/a0035712. Go to original source... Go to PubMed...
  17. Curran HV, Kleckham J, Bearn J, et al. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: A dose-response study. Psychopharmacology (Berl). 2001;154(2):153-60. doi: 10.1007/s002130000628. Go to original source... Go to PubMed...
  18. Schulte MHJ, Cousijn J, den Uyl TE, et al. Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. Clin Psychol Rev. 2014;34(7):531-50. doi: 10.1016/j.cpr.2014. 08. 002. Go to original source...
  19. Gruber SA, Tzilos GK, Silveri MM, et al. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol. 2006;14(2):157-64. doi: 10.1037/1064-1297. 14. 2.157. Go to original source...
  20. Soyka M, Lieb M, Kagerer S, et al. Cognitive functioning during methadone and buprenorphine treatment. J Clin Psychopharmacol. 2008;28(6):699-703. doi: 10.1097/jcp.0b013e31818a6d38. Go to original source... Go to PubMed...
  21. Spowart KM, Reilly K, Mactier H, et al. Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone. Front Pediatr. 2023;11:1118634. doi: 10.3389/fped.2023.1118634. Go to original source... Go to PubMed...
  22. Fjærli HH, Sømhovd MJ, Bergly TH. Difference between psychostimulant users and opioid users in recovery of cognitive impairment, measured with the Montreal Cognitive Assessment (MoCA®). J Subst Use. 2021;27(6):611-5. doi: 10.1080/14659891.2021.1967487. Go to original source...
  23. Rezapour T, Hatami J, Farhoudian A, et al. Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder. J Subst Abuse Treat. 2021;131:108558. doi: 10.1016/j.jsat.2021.108558. Go to original source... Go to PubMed...
  24. Jang SE, Bradshaw YS, Carr DB. Comparison of the impacts of under-treated pain and opioid pain medication on cognitive impairment. Cureus. 2022;14(4):e22037. doi: 10.7759/cureus.22037. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.